Pfizer licenses its DDP-4 diabetes candidate to Russia's ChemRar
This article was originally published in Scrip
Executive Summary
Pfizer has granted the SatRx company of Russia's ChemRar High Tech Centre the exclusive worldwide rights, outside of China, to its dipeptidyl peptidase-4 (DDP-4) inhibitor, PF-00734200, for type 2 diabetes. Established in 2010, SatRx is focused on diabetes, obesity and other metabolic diseases and is housed in ChemRar, a private R&D centre and business incubator clustered near Moscow, and it has a number of ongoing R&D projects (scripintelligence.com, 29 March 2011).